Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Docetaxel in Advanced Urothelial Carcinoma
NCT02426125Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of ramucirumab in urothelial carcinoma (UC), sponsored by Eli Lilly and Company. Started Jul 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02426125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426125.